Bio-Techne ordered to pay former CEO Kummeth about $36 million in option arbitration
On February 26, 2025, an arbitrator ruled in favor of former CEO Charles R. Kummeth in a dispute over 794,400 vested options that the company had treated as expired following an administrative error. The company must pay Kummeth approximately $35,978,000 for the options, plus about $980,000 in interest and about $234,000 in legal fees and costs, which will reduce shareholder value.
Key points
- Arbitrator's order dated February 26, 2025 found Kummeth would have exercised his options before the August 9, 2024 expiration date.
- Payment for the options is approximately $35,978,000, measured by the 30-day average closing price before the Award Agreement expiration date.
- Additional amounts are approximately $980,000 in interest and approximately $234,000 in legal fees and costs.
- The dispute arose from an administrative error in the stock plan platform, which showed an October 26, 2024 expiration date.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 04, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.